Pharmacotherapy: GLP-1R agonists - The new weapon against obesity?

摘要

Treatment with agonists of the glucagon-like peptide 1 receptor (GLP-1R) induces weight loss in patients with overweight or obesity irrespective of the presence of type 2 diabetes mellitus, report Danish researchers.Over the past decade, GLP-1—a gut hormone secreted after nutrient ingestion—has emerged not only as an essential regulator of blood glucose levels (through its effect on glucose-stimulated insulin secretion and inhibition of glucagon release) but also as a therapeutic target for the treatment of type 2 diabetes mellitus. The GLP-1 R agonists exenatide and liraglutide—which, unlike GLP-1, are not rapidly degraded by dipeptidyl peptidase 4—are known to produce modest but significant and sustained weight loss in patients with diabetes mellitus.